Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Chemed (NYSE:CHE) Corporation on Tuesday, setting a price target of $580, which is approximately 24.46% above the present share price of $466.01.
Wiederhorn expects Chemed Corporation to post earnings per share (EPS) of $7.12 for the second quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Chemed, with an average price target of $590.
The analysts price targets range from a high of $600 to a low of $580.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $533.29 million and a net profit of $145.13 million. The company's market cap is $7.44 billion.
According to TipRanks.com, Oppenheimer analyst Michael Wiederhorn is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 24.0% and a 77.32% success rate.
Chemed Corp . engages in the provision of healthcare and maintenance services. It operates through the following segments: VITAS and Roto-Rooter. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers. The Roto-Rooter segment includes plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers. The company was founded in 1970 and is headquartered in Cincinnati, OH.